Moleculin Biotech, Inc. (MBRX): Free Cash Flow
-$22.73M
Year ended 2025-12-31
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$22.73M | n/m | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | -$23.88M | n/m | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | -$23.71M | n/c | 2025-03-21, From 2023-01-01 |
| 2022-12-31 | -$27.71M | n/m | 2024-03-22, From 2022-01-01 |
| 2021-12-31 | -$18.97M | n/m | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | -$18.15M | n/m | 2022-03-24, From 2020-01-01 |
| 2019-12-31 | -$17.25M | n/m | 2021-03-24, From 2019-01-01 |
| 2018-12-31 | -$12.62M | n/m | 2020-03-19, From 2018-01-01 |
| 2017-12-31 | -$7.35M | n/m | 2019-02-21, From 2017-01-01 |
| 2016-12-31 | -$3.79M | n/a | 2018-03-28, From 2016-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | -$22.73M | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $7.39B | +16.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $12.85B | -7.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $9.07B | -7.7% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.70B | -0.7% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $28.84M | +101.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $12.36B | -31.7% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | -$15.98M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$27.91M | n/m |
Compare MBRX, ABT, BMY, PFE side by side · Screen every company in Pharmaceutical Preparations ↗